Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials

被引:0
|
作者
Z Zou
G-L Xi
H-B Yuan
Q-F Zhu
X-Y Shi
机构
[1] Changzheng Hospital,Department of Anesthesiology
[2] Second Military Medical University,undefined
[3] Center for New Drug Evaluation,undefined
[4] Institute of Basic Medical Science,undefined
[5] Second Military Medical University,undefined
来源
关键词
telmisartan; angiotensin II type 1 receptor blockers; angiotensin-converting enzyme inhibitors; antihypertensive agents;
D O I
暂无
中图分类号
学科分类号
摘要
Telmisartan and angiotensin-converting enzyme inhibitors (ACEIs) are both effective and widely used antihypertensive drugs targeting renin–angiotensin–aldosterone system. The study aimed to estimate the efficacy and tolerability of telmisartan in comparison with different ACEIs as monotherapy in the treatment of hypertension. Cochrane Central Register of Controlled Trials, PubMed and Embase were searched for relevant studies. A meta-analysis of all randomized controlled trials fulfilling the predefined criteria was performed. A random-effect model was used to account for heterogeneity among trials. Twenty-eight randomized controlled trials involving 5157 patients were ultimately identified out of 721 studies. Telmisartan had a greater diastolic blood pressure (DBP) reduction than enalapril (weighted mean difference (WMD) 1.82, 95% confidence interval (CI) 0.66–2.99), ramipril (WMD 3.09, 95% CI 1.94–4.25) and perindopril (WMD 1.48, 95% CI 0.33–2.62). Telmisartan also showed a greater DBP response rate than enalapril (relative risk (RR) 1.15, 95% CI 1.05–1.26), ramipril (RR 1.34, 95% CI 1.11–1.61) and perindopril (RR 1.22, 95% CI 1.05–1.41). There was no statistical difference in DBP reduction or therapeutic response rate between telmisartan and lisinopril (WMD −0.30, 95% CI −0.65 to 0.05; RR 0.99, 95% CI 0.80–1.23, respectively). Telmisartan had fewer drug-related adverse events than enalapril (RR 0.57, 95% CI 0.44–0.74), ramipril (RR 0.44, 95% CI 0.26–0.75), lisinopril (RR 0.70, 95% CI 0.56–0.89) and perindopril (RR 0.52, 95% CI 0.28–0.98). The meta-analysis indicates that telmisartan provides a superior BP control to ACEIs (enalapril, ramipril and perindopril) and has fewer drug-related adverse events and better tolerability in hypertensive patients.
引用
收藏
页码:339 / 349
页数:10
相关论文
共 50 条
  • [1] Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials
    Zou, Z.
    Xi, G-L
    Yuan, H-B
    Zhu, Q-F
    Shi, X-Y
    JOURNAL OF HUMAN HYPERTENSION, 2009, 23 (05) : 339 - 349
  • [2] Angiotension-converting enzyme in treatment of hypertension in patients with chronic kidney disease
    Bunjak, L.
    Milovancevic, S.
    Vukotic, J.
    SWISS MEDICAL WEEKLY, 2009, 139 (33-34) : 104S - 104S
  • [3] Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension
    Xi, Gui-Lin
    Cheng, Jin-Wei
    Lu, Guo-Cai
    AMERICAN JOURNAL OF HYPERTENSION, 2008, 21 (05) : 546 - 552
  • [4] Meta-Analysis of Randomized Controlled Trials Compared Telmisartan with Losartan in the Treatment of Patients With Hypertension
    Hoefler-Speckner, Simone
    JOURNAL FUR HYPERTONIE, 2008, 12 (03): : 39 - 39
  • [5] Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials
    Lv, Yan
    Zou, Zui
    Chen, Guan-min
    Jia, Huai-Xin
    Zhong, Jing
    Fang, Wei-Wu
    BLOOD PRESSURE MONITORING, 2010, 15 (04) : 195 - 204
  • [6] Meta-Analysis of Randomized Controlled Trials on Effect of Angiotensin-Converting Enzyme Inhibitors on Cancer Risk
    Sipahi, Ilke
    Chou, Josephine
    Mishra, Prasun
    Debanne, Sara M.
    Simon, Daniel I.
    Fang, James C.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (02): : 294 - 301
  • [7] Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials
    Vukadinovic, Davor
    Vukadinovic, Aleksandra Nikolovska
    Lavall, Daniel
    Laufs, Ulrich
    Wagenpfeil, Stefan
    Boehm, Michael
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (03) : 652 - 660
  • [8] Hypertension: meta-analysis of randomized controlled trials
    Chen, Ken
    Kou, Xun
    Han, Yu
    Zhou, Lin
    Zeng, Chunyu
    CARDIOLOGY, 2013, 126 : 165 - 165
  • [9] Randomized controlled trials of acupuncture for the treatment of essential hypertension: a meta-analysis
    Lu Yuqing
    Li Lingjie
    Wang Zhaoqin
    Huang Yan
    Zhong Rui
    Xu Jing
    Liu Huirong
    Wu Huangan
    Cheng Ling
    Wu Luyi
    JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE, 2023, 21 (04) : 315 - 329
  • [10] Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension
    He, Bing
    Zhang, Fengwen
    Li, Xueying
    Tang, Chaoshu
    Lin, Guosheng
    Du, Junbao
    Jin, Hongfang
    CIRCULATION JOURNAL, 2010, 74 (07) : 1458 - 1464